{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:38:25Z","timestamp":1786804705701,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,12,30]],"date-time":"2012-12-30T00:00:00Z","timestamp":1356825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00520-012-1696-0","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T22:42:38Z","timestamp":1356734558000},"page":"1561-1568","source":"Crossref","is-referenced-by-count":28,"title":["Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy"],"prefix":"10.1007","volume":"21","author":[{"name":"for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"Olver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grimison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C.","family":"Toner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Harrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,30]]},"reference":[{"key":"1696_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djq245","volume":"102","author":"PS Grimison","year":"2010","unstructured":"Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC (2010) Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 102:1\u201310","journal-title":"J Natl Cancer Inst"},{"key":"1696_CR2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","volume":"15","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u2013130","journal-title":"Support Care Cancer"},{"key":"1696_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00520-004-0699-x","volume":"13","author":"MG Kris","year":"2005","unstructured":"Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85\u201396","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"1696_CR4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00520-010-0920-z","volume":"19","author":"LH Einhorn","year":"2011","unstructured":"Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant review and consensus statement. Supportive Care in Cancer 19(Suppl 1):S1\u2013S4","journal-title":"Supportive Care in Cancer"},{"issue":"suppl 5","key":"1696_CR5","first-page":"232","volume":"21","author":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Cark-Snow RA, Esperson BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MJ, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO\/MASCC Guidelines Working Group","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Cark-Snow RA, Esperson BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MJ, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO\/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):232\u2013243","journal-title":"Ann Oncol"},{"issue":"9258","key":"1696_CR6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(00)04165-9","volume":"357","author":"GC Toner","year":"2001","unstructured":"Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomized trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357(9258):739\u201345","journal-title":"Lancet"},{"key":"1696_CR7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","volume":"35","author":"FD Tattersall","year":"1996","unstructured":"Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLoed AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ (1996) Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35:1121\u20131129","journal-title":"Neuropharmacology"},{"key":"1696_CR8","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Juie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Juie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"1696_CR9","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocoll 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1696_CR10","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","volume":"97","author":"SP Chawla","year":"2003","unstructured":"Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Scmidt C, Taylor A, Carides AD, Evans JK, Horgan JK (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290\u20132300","journal-title":"Cancer"},{"key":"1696_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McRea","year":"2003","unstructured":"McRea JB, Majumbar AK, Goldberg MR, Goldberg MR, Iwamato M, Gargano C, Panebianco DL, Hesny M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17\u201324","journal-title":"Clin Pharmacol Ther"},{"key":"1696_CR12","doi-asserted-by":"crossref","unstructured":"Grimison PS, Thomson DB, Stockler MR, et al. (2011) Accelerated BEP for advanced germ cell tumours: an Australian multicenter phase I\/II trial. J Clin Oncol 29 (Suppl; abstr 4561)","DOI":"10.1200\/jco.2011.29.15_suppl.4561"},{"key":"1696_CR13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","volume":"104","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F, Aprepitant Moderately Emetogenic Chemotherapy Study Group (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548\u20131555","journal-title":"Cancer"},{"issue":"11","key":"1696_CR14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","volume":"15","author":"L Einhorn","year":"2007","unstructured":"Einhorn L, Brames M, Dreicer R, Nichols CR, Cullen MT Jr (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Supportive Care in Cancer 15(11):1293\u2013300","journal-title":"Supportive Care in Cancer"},{"key":"1696_CR15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","volume":"45","author":"K Jordan","year":"2009","unstructured":"Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf H-H, Schmoll H-J (2009) Safety and efficacy of a triple antiemetic combination with the the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45:1184\u20131187","journal-title":"Eur J Cancer"},{"key":"1696_CR16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2354.2007.00872.x","volume":"17","author":"A Molassiotis","year":"2008","unstructured":"Molassiotis A, Stricker CT, Eaby B, Velders L, Coventary PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl) 17:444\u2013453","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1696_CR17","first-page":"257","volume":"5","author":"RW D\u2019Acquisto","year":"1986","unstructured":"D\u2019Acquisto RW, Tyson LB, Gralla RJ et al (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1696_CR18","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group Study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"1696_CR19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","volume":"20","author":"PJ Hesketh","year":"2011","unstructured":"Hesketh PJ, Wright O, Rosati G, Russo M, Levin J, Lane S, Moiseyenko V, Dube P, Kopp M, Makhson A (2011) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicentre, randomized, double-blind, active-controlled, two arm parallel group study. Support Care Cancer 20:1471\u20131478","journal-title":"Support Care Cancer"},{"key":"1696_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TCRM.S2345","volume":"4","author":"IN Olver","year":"2008","unstructured":"Olver IN (2008) Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag 4:1\u20136","journal-title":"Ther Clin Risk Manag"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1696-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1696-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1696-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T13:50:13Z","timestamp":1562507413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1696-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,30]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1696-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,30]]}}}